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ABSTRACT 
Organic Anion Transporting Polypeptides (OATPs), encoded by genes of the Solute Carrier 
Organic Anion (SLCO) family, are transmembrane proteins involved in the uptake of various 
compounds of endogenous or exogenous origin. In addition to their physiological roles, 
OATPs influence the pharmacokinetics and drug-drug interactions of several clinically 
relevant compounds. To examine the function and molecular interactions of human OATPs, 
including several poorly characterized family members, we expressed all 11 human OATPs at 
high levels in the baculovirus-Sf9 cell system. We measured the temperature- and inhibitor-
sensitive cellular accumulation of sodium fluorescein and fluorescein-methotrexate, two 
fluorescent substrates of the OATPs, OATP1B1 and 1B3. OATP1B1 and 1B3 were functional 
in Sf9 cells, showing rapid uptake (t1/2(fluorescein-methotrexate) 2.64 and 4.16 min, and 
t1/2(fluorescein) 6.71 and 5.58 min for OATP1B1 and 1B3, respectively) and high-affinity 
transport (Km(fluorescein-methotrexate) 0.23 and 0.53 M, and Km(fluorescein) 25.73 and 38.55 M 
for OATP1B1 and 1B3, respectively) of both substrates. We found that sodium fluorescein is 
a general substrate of all human OATPs: 1A2, 1B1, 1B3, 1C1, 2A1, 2B1, 3A1, 4A1, 4C1, 
5A1 and 6A1, while fluorescein-methotrexate is only transported by 1B1, 1B3, 1A2 and 2B1. 
Acidic extracellular pH greatly facilitated fluorescein uptake by all OATPs, and new 
molecular interactions were detected (between OATP2B1 and Imatinib, OATP3A1, 5A1 and 
6A1 and estradiol 17-D-glucuronide, and OATP1C1 and 4C1 and prostaglandin E2). These 
studies demonstrate, for the first time, that the insect cell system is suitable for the functional 
analysis of the entire human OATP family, and for drug-OATP interaction screening. 
Abbreviations 
CA: cholic acid 
CsA: cyclosporin A 
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EG: estradiol 17-D-glucuronide 
HEPES: 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
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1. INTRODUCTION
The role of uptake transporters in drug pharmacokinetics is being increasingly 
recognized. One group of uptake transporters gaining recognition for their relevance to the 
absorption and toxicity of clinically relevant drugs are the Organic Anion Transporting 
Polypeptides (OATPs) [1, 2]. OATPs are plasma membrane proteins that mediate sodium and 
ATP-independent transport of large (over 300 Da), charged or amphipathic compounds into 
cells [3-5]. The 11 known OATPs are encoded by genes of the Solute Carrier Organic Anion 
(SLCO) family. 
Based on their substrate specificity, OATPs can be divided into two groups.  OATP1A2, 1B1, 
1B3 and 2B1 transport a wide range of compounds, from bile acids and hormones, to various 
therapeutics including statins, antiviral agents and antibiotics. Conversely, OATP3A1, 1C1, 
2A1, 4A1, 4C1 and 5A1 have been documented to transport only a few compounds [4, 6, 7]. 
Currently, there is no published information on the function or substrate specificity of 
OATP6A1, primarily due to the lack of convenient expression systems and functional assays. 
OATP1B1 and 1B3 are important in the hepatic re-uptake of bile acids, bilirubin and in the 
hepatic clearance of several drugs [2]. Mutations in SLCO1B1 and 1B3 result in Rotor 
syndrome, a benign disorder characterized by increased serum bilirubin levels. The role of the 
1A/1B family of OATPs in the hepatic disposition of bile salts, bilirubin and therapeutic 
drugs was demonstrated via knock out [8] and transgenic mouse models [9]. Deletion of the 
mouse orthologue of OATP1C1 results in mild, brain-specific hypothyroidism confirming the 
function of this protein in thyroid transport [10]. The physiological relevance of the remaining 
OATPs remains to be elucidated. 
Several single nucleotide polymorphisms (SNPs) in OATP-encoding genes have been linked 
to altered drug pharmacokinetics, suggesting that these transporters play an important role in 
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in the uptake and elimination of drugs [11]. Population studies and in vitro experiments 
demonstrate that SNPs in OATP1A2, 1B1, 1B3 and 2B1 affect the uptake of hormones and 
antihistamines, as well as cholesterol-lowering and anticancer drugs [11].  OATPs also show 
altered expression in various cancer cells. Liver-specific OATP1B1 and 1B3 were down-
regulated in liver cancers, and highly upregulated in tumors of the ovarian gland (1B1), colon 
(1B1 and 1B3), breast (1B3), prostate (1B3) and lung (1B3) [1]. Similarly, OATP6A1, 
normally restricted to the testes, was found in cancerous tissues of the bladder, brain and lung 
[1]. The potential diagnostic and therapeutic value of the cancer-specific localization of 
OATPs is currently under intense investigation. 
Despite the clear clinical relevance, the substrate recognition patterns of only four members of 
the OATP family, 1A2, 1B1, 1B3 and 2B1 have been thoroughly investigated. The bottleneck 
in establishing the substrate/inhibitor profile of OATPs is the scarcity and high cost of 
radioactively labeled substrates. Mass spectrometry (MS) may be an alternative to assays 
based on radiolabeled substrates [12].  However, MS is more time-consuming and requires 
high protein expression levels to obtain an acceptable signal to noise ratio.  Contrary to these 
methods, the measurement of fluorescent substrates is sensitive, safe, relatively inexpensive 
and amenable to automatized detection. 
Sodium fluorescein (Na-Fluo) and fluorescein-methotrexate (Fl-MTX) have been shown to be 
suitable for the screening of potential OATP1B1/1B3-interacting compounds [13, 14]. 
Additionally, Fluo-3, indocyanine green and fluorescent bile acids have been shown to be 
readily transported by OATP1B1 and 1B3 [15-17]. However, fluorescent assays for the 
remaining members of the OATP family have not yet been described, and for 6A1, there are 
no known substrates. 
In this study, our aim was to develop a comprehensive, fluorescence-based functional assay to 
analyze the function of all known human OATPs. We expressed these proteins in the 
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baculovirus-insect cell expression system and developed a functional assay measuring the 
cellular uptake of Na-Fluo and Fl-MTX. We show that Na-Fluo is transported by all 11 
human OATPs, and, under optimal assay conditions, 1A2 and 2B1 are able to mediate the 
uptake of fluorescein-methotrexate. Our insect cell-based method provides the first 
fluorescent assay for the functional investigation of all human OATPs, which will facilitate 
further screening of potential OATP substrates and structure-function relationship analyses. 
2. Materials and Methods  
2.1. Materials 
Cholic acid (CA), glycocholic acid (GC), propidium iodide, prostaglandinE2 (PGE2), 
rifampicin (Rif), sodium fluorescein salt (Na-Fluo), taurocholic acid (TC) and ursolic acid 
(UA) were purchased from Sigma-Aldrich (Budapest, Hungary). Fluorescein-methotrexate 
(Fl-MTX) was obtained from Biotium, Inc. (Hayward, CA, US). Restriction endonucleases 
were from New England Biolabs, Ltd. (Ipswitch, MA, US). 
2.2. Plasmid constructs  
To generate the expression plasmids for human OATPs, we first engineered unique restriction 
sites that allowed for cloning of all human OATPs into the baculovirus transfer vector 
pAcUW21 (BD Biosciences, San Jose, CA, US). The modified plasmid, termed pAcUW-L2, 
was constructed by inserting the oligonucleotide linkers, 5’ 
GGCCGTGAATTCGGTACCTCGAGCTCGCGGCCGCT-3’ and 5’-
GATCAGCGGCCGCGAGCTCGAGGTACCGAATTCAC-3’,  between the BamHI and 
NotI sites of pAcUW21-L/ABCG2, a vector generated previously in our lab [18]. Full-length 
cDNA sequences encoding human OATPs were then introduced into pAcUW-L2 using the 
appropriate restriction sites. 
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OATP1A2, 1B3, 1C1, 2A1, 2B1, 4A1, 5A1 and 6A1 were obtained from the Harvard 
PlasmID Repository (Harvard Medical School, Boston, MA, US), and the cloning of 
OATP1B1 (Gene ID: AB026257), 3A1 variant 1 (AB031050) and 4C1 (353189) was 
performed using the previously constructed vector, pSPORT1 [19, 20]. OATP1B1 and 3A1 
transfer vectors were constructed by isolating the corresponding full-length OATP cDNA 
from pSPORT1, and then subcloning into the pAcUW21-L2 plasmid between the KpnI and 
NotI restriction endonuclease sites. Sequence analysis revealed that the OATP1B1 cDNA 
encodes a polymorphism (N130D, rs2306283), therefore, we reverted the sequence to wild-
type (Q9Y6L6.2) using site-directed mutagenesis. The primers used in the mutagenesis 
reaction were: 1B1-N130N for 5’-ACTAATATCAATTCATCAGAAAATTCAACA-3’, 
1B1-N130N rev 5’-TGTTGAATTTTCTGATGAATTGATATTAGT-3’. To generate the 
OATP6A1 construct, the corresponding cDNA was removed from a pBluescriptR vector 
(BC034976, HsCD00333181) using NotI and BamHI restriction enzymes, and subcloned into 
pAcUW21-L/ABCG2. Sequencing revealed that the vector HsCD00333181 contains a shorter 
isoform of 6A1, which is missing amino acids 206-267, compared to the canonical sequence 
(Q86UG4-1). The cDNA corresponding to the missing region was synthesized by ShineGene 
Molecular Bio-Technologies, Inc. (Shanghai, China), and subcloned into the pAcUW-21-
L/OATP6A1 isoform 2 vector between the NdeI and SpeI sites. The open reading frames of 
1A2 (BC042452, HsCD00333163), 1B3 (BC141525, HsCD00348132), 1C1 (BC022461, 
HsCD00332885), 2A1 (BC041140,  HsCD00338568), 2B1 (BC041095.1, HsCD00378878), 
4A1 (BC015727, HsCD00334491), 4C1 and 5A1 (BC137424, HsCD00342690) were 
amplified by HF PCR (Phusion® High-Fidelity PCR Kit, NEB, Ipswitch, MA, US) following 
the manufacturer’s instructions and using the following primers:  
1A2 
for GGAAGATCTGCGGCCGCGCCACCATGGGAGAAACTGAGAA 
rev ATTGAGCTCCTGCAGTTACAATTTAGTTTTCAAT 
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1B3 
for GTAAATGCGGCCGCAACTCGAGGCCACCATGGACCAACATCAACAT 
rev GTACATGCGGCCGCACTGCAGTTAGTTGGCAGCAGCATT 
1C1 
for TGTTTAAACTCTAGAGCCACCATGGACACTTCATCCAAAGAA 
rev TAACCTGCAGGCGGCCGCGTTTCTAAAGTTGAGTTTCCTTG 
2A1 
for GTAAATGCGGCCGCAAGAATTCGCCACCATGGGGCTCCTGCCCA 
rev GTACATGCGGCCGCTAAGCTTTCAGATGAGGCCTGCCGC 
2B1 
for GTAAATGCGGCCGCAAGAATTCGCCACCATGGGACCCAGGATAGG 
rev GTACATGCGGCCGCTAAGCTTTCACACTCGGGAATCCTC 
4A1 
for GGAAGATCTGATATCGCCACCATGCCCCTGCATCAGCTG 
rev ATTGAGCTCAAGCTTTCAGACGCTGCTCTGGAG 
4C1 
for GGAAGATCTGCGGCCGCGCCACATGAAGAGCGCCAAAGGT 
rev ATTGAGCTCAAGCTTTCACCCTTCTTTTACTAT 
5A1 
for TGTTTAAACTCTAGAGCCACCATGGACGAAGGCACTGGACTGC 
rev TAACCTGCAGGAGCGGCCGCCTTCTTCCATTTTCAAGCTTCAGGAGG 
 
The amplified fragments were digested using the appropriate restriction enzymes (1A2, 4A1 
and 4C1: BglII and SacI, 1B3: XhoI and NotI, 2A1 and 2B1: EcoRI and NotI, and 1C1 and 
5A1: PmeI and NotI) and subcloned into the pAcUW21-L2 plasmid. Because sequencing of 
the OATP4A1 construct revealed that the purchased cDNA contains a known SNP of 
OATP4A1 (232G>A (V78I), rs1047099), the canonical sequence (Q96BD0-1) was generated 
via QuickChange mutagenesis using the following primers: 5’AGGTGCGGTACGTCTCGG 
3’ (4A1 for and 5’CCGAGACGTACCGCACCT 3’ (4A1 reverse). The DNA sequences for 
all constructs were verified by sequencing analyses. 
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2.3. Maintenance of Sf9 cell cultures and generation of recombinant baculoviruses  
Sf9 (Spodoptera frugiperda) cells were grown in suspension culture using TNM-FH insect 
medium (Sigma Aldrich, Budapest, Hungary) supplemented with 10% fetal calf serum, 100 
units/ml penicillin and 100 μg/ml streptomycin, at 27°C. Recombinant baculoviruses, carrying 
the different human OATP cDNA sequences, were generated using the BaculoGold 
Transfection Kit (BD Biosciences, San Jose, CA, US) according to the manufacturer’s 
instructions. After several rounds of amplification, the virus stocks were stored at 4
o
C. 
Transport experiments were performed using the virus stocks that resulted in the highest 
OATP expression levels (as determined by Western blot). 
2.4. Immunodetection of OATPs 
Whole cell lysates of Sf9 cells (5-10 g) were separated on 7.5% Laemmli SDS-PAGE gels 
and transferred onto PVDF membranes. Immunoblotting was performed as described [18]. 
Membranes were incubated overnight with polyclonal antibodies. The antibodies used for the 
detection of OATP1A2, 1B1, 1B3, 1C1, 2B1, 3A1_v1 and 4A1 were previously described 
[19]. Antibodies against OATP2A1 (HPA013742), 4C1 (HPA036516), 5A1 (HPA025062) 
and 6A1 (HPA054126) were purchased from Atlas Antibodies (Stockholm, Sweden). The 
following antibody dilutions were used: 1/250 for 5A1, 1/500 for 1A2, 1B1, 2A1, 4C1 and 
6A1, and 1/1000 for 1B3, 1C1, 2B1, 3A1_v1 and 4A1.  After washing, PVDF membranes 
were incubated with 10,000-20,000x diluted, HRP-conjugated anti-rabbit secondary 
antibodies (Jackson ImmunoResearch, Suffolk, UK). Luminescence was detected using the 
Luminor Enhancer Solution kit by Thermo Scientific (Waltham, MA, US). 
2.5. Cellular Dye Uptake and Calculation of OATP Transport Activity 
The accumulation of fluorescent molecules was measured as previously described [18], with 
some minor modifications. Specifically, OATP-transduced Sf9 cells were collected 40 hours 
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post infection, washed once and suspended to 2–5 x 105cells/reaction in one of the following 
buffers: Buffer pH 7.4-8.4: 125 mM NaCl, 4.8 mM KCl, 1.2 mM CaCl2, 1.2 mM KH2PO4, 12 
mM MgSO4, 25 mM HEPES, and 5.6 mM glucose, with the pH adjusted to 8.4 or 7.4 using 10 
N NaOH or 10 N HCl, respectively. Buffer pH 4.5-7.4: 125 mM NaCl, 4.8 mM KCl, 1.2 mM 
CaCl2, 1.2 mM KH2PO4, 12 mM MgSO4, 25 mM MES, and 5.6 mM glucose, with the pH 
adjusted to 7.4, 6.5, 5.5 or 4.5 using 10 N NaOH or 1M HEPES.  
Cells (2–5 x 105/reaction) were pre-incubated in the presence or absence of inhibitors for 5 
min at 37°C. The reaction was initiated with the addition of two times concentrated Fl-MTX 
or Na-Fluo to a final concentration of 1 μM except for the measurement of concentration 
dependence. Uptake was stopped after 10 min (unless stated otherwise) of incubation at 37°C 
by adding 1 ml of ice-cold phosphate-buffered saline. The cells were kept on ice until flow 
cytometry analysis. The cellular fluorescence of 10,000 live cells was determined using an 
Attune® Acoustic Focusing Cytometer (Applied Biosystems, Life Technologies, Carlsbad, 
CA, US) at an excitation wavelength of 488 nm and an emission wavelength of 530/30 nm. 
Dead cells labeled with propidium iodide (1 μg/ml) were excluded. In control experiments, 
the levels of fluorescent substrates were analyzed in Sf9 cells expressing a Drosophila 
melanogaster telomerase subunit (the plasmid encoding this nuclear protein was a generous 
gift from Dr. Imre Boros at the Biological Research Center in Szeged, Hungary). Activity 
data were calculated by subtracting the background levels of fluorescence as measured in 
control cells. Functional data for each OATP represent the mean of at least 3 independent 
experiments performed on different days.  
 
2.6. Data analysis 
12 
 
Kinetic parameters of dye uptake were calculated using non-linear curve fitting (Hill fit) and 
Origin 8.6 software. A Student’s t-test was used to calculate any statistical significance. The p 
value for statistical significance was set at 0.05 (*), 0.01 (**) or 0.001 (***). 
 
3. RESULTS 
3.1. Transient expression of human OATP1B1 and OATP1B3 results in increased 
fluorescein-methotrexate and Na-fluorescein uptake in Sf9 cells 
The baculovirus Sf9 (Spodoptera frugiperda) insect cell expression system is a well-
established tool to express membrane proteins. This system has two main advantages over 
other expression systems.  Protein expression levels in Sf9 cells are much higher than those 
achieved in mammalian cell lines, and, unlike in yeast or bacterial systems, the proper routing 
of heterologous proteins is unaffected [21-23]. Interestingly, with the exception of OATP2B1, 
the applicability of this system for the analysis of human OATPs has not yet been described 
[24].  
First, we expressed the two best characterized members of the OATP family, OATP1B1 and 
1B3, in Sf9 cells. The immunoblot in Figure 1A shows that the heterologous proteins were 
efficiently expressed in the baculovirus-infected insect cells. The functionality of OATP1B1 
and 1B3 in this system was tested by measuring the cellular accumulation of two well-
described substrates. The baculovirus-insect cell system is a transient expression system, 
where virus infection results in the lysis of cells. However, we have previously demonstrated 
that at 36-40 hours post-infection, the levels of the heterologously-expressed protein are at 
near maximum, while 25-30 % of the cells still have intact plasma membranes [18]. Dead 
cells may be readily excluded from the analysis based on propidium-iodide positivity, and the 
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uptake of Fl-MTX or Na-Fluo can be selectively measured within intact cells that express 
high levels of the heterologously-expressed protein.  
As shown in Figure 1B, Sf9 cells transduced with OATP1B1 and 1B3 cDNA exhibit 
increased accumulation of Fl-MTX compared to control cells infected with a recombinant 
virus containing the cDNA of an unrelated protein. The observed transport was rapid, 
showing saturation kinetics with the following t1/2 values: 2.64 +/- 0.53 and 4.16 +/- 0.28 min 
for 1B1 and 1B3, respectively. OATP1B1- and 1B3-mediated uptake was absent at 4
o
C (not 
shown) and in the presence of a known inhibitor, cyclosporin A [25]. The Km values of 0.23 
+/- 0.04 M and 0.53 +/- 0.40 M for 1B1 and 1B3, respectively, were lower than those 
observed in mammalian cells  [14] (Figure 1, Panels C and D).  
The transport of another well-known fluorescent substrate, Na-Fluo, in OATP1B1 or 1B3 
overexpressing Sf9 cells (Figure 2A) was similar to that observed for Fl-MTX, showing a 
rapid uptake (t1/2 6.71 +/- 2.33 and 5.58 +/- 0.11 for 1B1 and 1B3, respectively) and Km values 
of 25.73 +/- 4.68 M and 38.55 +/- 15.00 M for 1B1 and 1B3, respectively (Figure 2B and 
C). These results correspond to those obtained in mammalian cells [13].  
To further characterize OATP1B1/1B3-mediated transport, we examined the effect of 
estradiol D-glucuronide, various bile acids and other previously identified 
OATP1B1/1B3-interacting compounds on the uptake of Fl-MTX or Na-Fluo (Figure 3). We 
observed a significant inhibitory effect on OATP1B1/1B3-mediated transport of the majority 
of these compounds (but not in control cells), confirming that the observed uptake in insect 
cells was due to the activity of the overexpressed human proteins. However, the inhibitory 
potential of the tested compounds differed for the two substrates used, which may be due to 
potential differences in compound-specific binding sites.  
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3.2. Functional expression of the entire human OATP family in Sf9 insect cells reveals 
that fluorescein is a pan-OATP substrate 
After confirming that the insect cell system is suitable for the functional expression of 
OATP1B1 and 1B3, we generated Sf9 cells overexpressing the remaining 9 human OATPs:  
1A2, 1C1, 2A1, 2B1, 3A1, 4A1, 4C1, 5A1 and 6A1. The expression levels of all proteins 
were determined via Western blotting (Figure 4A). Specific bands corresponding to the core-
glycosylated proteins were detected in each case [26]. 
Using transport conditions that were optimized for OATP1B1 and 1B3 (10 min incubation at 
37
o
C, pH 7.4, using 1 M of substrate), we measured Na-Fluo and Fl-MTX uptake in insect 
cells that expressed individual members of the entire human OATP family. As shown in 
Figure 4B, all members of the human OATP family are able to transport fluorescein. In 
contrast, Fl-MTX was only transported by OATP1B1 and 1B3 (Figure 4C).  
3.3. Effect of pH on Na-fluorescein and Fl-MTX transport  
The above described experiments were performed at pH 7.4. However, previous studies 
demonstrated that acidic extracellular pH increases the transport of various compounds by the 
majority of OATPs [27]. As Sf9 cells are grown at pH 6.2, it was possible that the use of a 
neutral transport buffer precluded the formation of the inwardly directed H
+
 gradient 
necessary for optimal transport by pH-sensitive OATPs. To address this issue and to 
investigate how the extracellular milieu may influence OATP transport in insect cells, we 
tested the effect of various buffers, ranging from pH 4.5 to pH 8.5, on OATP1B1/1B3-
mediated uptake. Using pH-adjusted buffers, we demonstrate that OATP1B1 and 1B3 are able 
to transport Fl-MTX over a wide pH range, although maximal activity is observed at a neutral 
pH (Figure 5A). Interestingly, however, Na-Fluo transport was significantly enhanced in an 
acidic extracellular environment, suggesting that the transport of Na-Fluo may be triggered by 
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a proton gradient (Figure 5B). The emission intensity of fluorescein decreases at acidic pH 
values ([28], and data not shown). Therefore, the elevated Na-Fluo signal observed under 
acidic pH conditions likely reflects increased Na-Fluo uptake and not a non-specific increase 
in substrate fluorescence.  
Because the transport of Na-Fluo by OATP1B1 and 1B3 was significantly enhanced under 
acidic assay conditions, we examined the effect of acidic pH on the transport activity of the 
entire human OATP panel. Investigation of OATP1B1/1B3-mediated transport revealed that 
the optimal pH range for Fl-MTX transport in Sf9 cells is 6.5-7.4, while that of Na-Fluo is 
4.5-5.5. To achieve maximal activity under physiologically relevant conditions, we tested Fl-
MTX and Na-Fluo uptake by all human OATPs at pH 6.5 and 5.5, respectively. Consistent 
with the results observed for OATP1B1 and 1B3, acidification of the extracellular milieu 
resulted in increased Na-fluorescein transport by all human OATPs despite the increased 
background fluorescence (Figure 6A). In contrast, an acidic environment only activated Fl-
MTX transport for OATP1A2 and 2B1, as the remaining OATPs were inactive (Figure 6B).  
3.4. Effect of inhibitors 
To determine whether the insect cell-based Na-Fluo or Fl-MTX assay is suitable for testing 
substrates/inhibitors of all human OATPs, we repeated the assays in the presence of several 
previously described OATP-interacting compounds. Figure 7 shows that despite lower 
baseline transport rates, the transport of Fl-MTX by OATP1A2 and 2B1 was inhibited by 
CsA, ursolic acid, bile acids, PGE2, MTX and Imatinib. The optimized assay conditions 
allowed for the identification of several novel OATP-interacting compounds. We demonstrate 
that ursolic acid, a pentacyclic triterpenoid found in fruit rind influences the activity of 
OATP1A2. Further, we find that estradiol 17--D-glucuronide, glycocholate and Imatinib 
modulate the function of OATP2B1. 
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Similar results were obtained using the Na-Fluo uptake assay (Figure 8). We found that the 
transport activity for each human OATP was influenced by at least one test compound.  
Cyclosporin A inhibited the uptake mediated by OATP1B3, 1A2, 2A1 and 2B1, prostaglandin 
E2 decreased the transport by OATP1A2, 1C1, 2A1, 2B1 and 4C1, and ursolic acid by 
OATP2A1. Interestingly, estradiol 17--D-glucuronide and ursolic acid induced the Na-Fluo 
transport activity of several OATPs, suggesting that Na-Fluo transport may be allosterically 
activated by these compounds. 
 
4. Discussion  
Members of the OATP family are major determinants of the uptake and elimination of drugs 
[2, 29]. Administration of drugs or food components that are either substrates or inhibitors of 
OATPs may result in adverse drug toxicity [29]. Therefore, the investigation of a potential 
interaction between OATPs with known pharmacological relevance (OATP1B1 and 1B3) and 
a new molecular entity is recommended by the International Transporter Consortium [30], the 
US Food and Drug Administration and by the European Medicines Agency. In addition to 
OATP1B1 and 1B3, OATP1A2 and 2B1 are also known to transport a wide variety of 
substrates. Since these transporters are expressed at high levels in the intestine (2B1), liver 
(2B1) and the blood-brain barrier (1A2, 2B1), they should also be considered as important 
determinants of drug pharmacokinetics. Additionally, several OATPs show cancer-specific 
expression and therefore may be exploited in targeted drug delivery [1, 31]. Clearly, 
information on the substrate specificity and the role in ADME-T (Absorption, Distribution, 
Metabolism, Excretion and Toxicity) for all of the human OATPs is needed. 
Given the absence of suitable functional assays, most members of the human OATP family 
remain poorly characterized. The major impediment to the investigation of OATP function is 
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the limited availability of radioactively- or fluorescently-labeled substrates and OATP-
specific inhibitors. Functional studies are also hindered by the limited number of cellular 
models with well-characterized transporter expression. To address these issues, we 
established an insect cell-based fluorescent transport assay for the investigation of the entire 
human OATP family. The main advantage of this approach compared to mammalian 
expression systems is the high level of protein expression, and therefore, the lack of a 
significant background transport activity. However, to date, only OATP2B1 was studied in 
insect cells. Tschantz and colleagues demonstrated functional expression of OATP2B1 in Sf9 
insect cells, with saturable uptake of [
3
H]estrone-3-sulphate [24]. In this study, we focused on 
the narrow window of time when the cells express high levels of the transporter, but are still 
viable. This setup enabled the measurement of OATP-mediated intracellular accumulation of 
fluorescent substrates in intact cells. Assays using fluorescent compounds are exceptionally 
suited for the measurement of transport activity given the relative low cost of test substrates, 
the sensitivity of the transport assay and the potential for application in a high-throughput 
setup. However, fluorescent substrate-based transport assays were available previously only 
for OATP1B1 and 1B3 [13-17, 32].  
Proteins overexpressed in the insect cell system are core-glycosylated [26] and several studies 
indicated that the lack of N-glycosylation impairs OATP function [24, 33-35]. To assess the 
functionality of OATPs expressed in Sf9 cells, we first tested two well-characterized OATPs, 
OATP1B1 and 1B3, for their ability to transport known substrates. We found that OATP1B1 
and 1B3 mediate a rapid, saturable, temperature- and inhibitor-sensitive uptake of Na-Fluo 
and Fl-MTX (Figures 1 and 2) similar to that observed in mammalian cells [13, 14]. 
Moreover, we demonstrated that known OATP1B-interacting compounds inhibit the uptake 
activity of both transporters, although the degree of inhibition differed for each substrate 
(Figure 3). The molecular mechanism underlying this substrate-dependent inhibition, a well-
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documented characteristic of OATP1B transporters, is likely due to the difference in affinity 
of the binding site for the individual substrates [14]. Our data suggest that several assays, 
using a variety of substrates, will be required to evaluate the pharmacological relevance of 
OATP-drug interactions. It has also to be noted that our results do not reveal the mechanism 
of inhibition, as compounds interacting with the transport of the fluorescent test substrate may 
be competitive or noncompetitive inhibitors. 
Several laboratories have found that the acidic extracellular milieu stimulates OATP-mediated 
transport [27, 36-42]. In the human body, acidic environments may be found under both 
physiological (in the intestine and kidney) and pathological conditions (in tumors, during 
inflammation or liver disease). Therefore, a pH-dependent activation of OATP function may 
provide tissue-specific or local regulation of these proteins [43]. When we investigated the pH 
dependence of OATP1B1/1B3-mediated transport (Figure 5), we found that Fl-MTX 
transport is maximal at near neutral pH, while Na-Fluo uptake is significantly increased in an 
acidic environment. The other OATPs had low level Na-Fluo transport at pH 7.4 (Figure 4B) 
even when higher substrate concentrations (5-10 M) and a longer incubation time (30 
minutes) were used (data not shown). Lowering the pH to 5.5, however, resulted in a 
significant increase in Na-Fluo transport by all OATPs (Figure 6A), demonstrating that Na-
Fluo is a general, pH-induced OATP substrate.  The precise mechanism by which the acidic 
milieu triggers OATP transport is not fully understood. A low extracellular pH (low [H]
+
EC) 
may result in the protonation of the transporter, i.e. on a pH-sensitive histidine (His) residue 
located in the third transmembrane domain region [27], or it may alter the charge of the 
transported molecule. Leuthold and colleagues demonstrated that OATP1C1, lacking the pH 
sensor His, is not activated by an acidic extracellular milieu [27]. Although we found that 
OATP1C1-mediated transport was activated by low [H]
+
EC, this discrepancy may be due to 
the different substrates that were used. 
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The Na-Fluo assay is the first transport assay suitable for the characterization of the entire 
human OATP family. Using a slightly acidified transport buffer (pH 6.5), we identified Fl-
MTX as a new substrate of OATP1A2 and 2B1 (Figure 6B), suggesting that Fl-MTX can also 
be used to test substrate interactions for these transporters (Figure 7). The identification of 
physiological substrates is of particular importance for poorly characterized members of the 
OATP family, including OATP5A1, which has only been documented to transport quercetin 
[6], and OATP6A1, whose function and physiological substrates remain unknown. The 
relevance of a functional assay encompassing the entire human OATP family is that it may 
serve as a tool for the identification of new molecular interactions. To test if our assay is able 
to identify new substrates and inhibitors, we tested and confirmed previously documented 
interactions of OATP1A2, 1B1, 1B3 and 2B1 with bile acids, cyclosporin A, PGE2 and 
methotrexate (Figures 3, 7 and 8). Furthermore, we identified novel interacting compounds: 
UA for 1A2, 2A1, 3A1, 4A1, 4C1 and 6A1, cyclosporin A for 2A1, EG for 3A1, 5A1 and 
6A1, and PGE2 for 1C1 and 4C1 (Figures 7 and 8). These data indicate a potential role for 
new members of the family (OATP3A1, 5A1 and 6A1) in hormone transport. Given that 
OATP5A1 and 6A1 expression levels are elevated in various cancers [1, 44], these findings 
may have significant implications regarding the survival of hormone-dependent tumors.  The 
results from our fluorescent assay analysis revealed novel interacting compounds (estradiol 
17-D-glucuronide, glycocholate and Imatinib), even for the relatively well-characterized 
2B1 (Figure 7). The interaction between OATP2B1 and Imatinib, a Bcr-Abl inhibitor used in 
the treatment of chronic myeloid leukemia, supports the notion that SNPs in SLCO2B1 may 
influence Imatinib pharmacokinetics resulting in inter-individual differences in therapy 
response [45]. 
Our assay also revealed unexpected interactions. In contrast to De Bruyn et al., we found 
significant Na-Fluo transport mediated by OATP2B1 at pH 7.4 [13]. In the case of 
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OATP1B1, Na-Fluo transport at pH 5.5 was activated, rather than inhibited, by cyclosporin A, 
EG, PGE2 and UA. This activating effect appeared to be pH-specific, as these compounds 
inhibited Na-Fluo uptake at pH 7.4 (Figure 3). In experiments not documented here, we found 
a similar, pH-dependent activation of Fl-MTX transport by several known interacting 
compounds. A similar activating effect was found by EG and UA, which enhanced the Na-
Fluo transport activity of 3A1, 5A1 6A1, and 3A1, 4A1, 4C1 and 6A1, respectively (Figure 
8). These data suggest that transport activity is allosterically modulated, a mechanism 
previously documented for OATP1B3 and 2B1 [14, 46, 47]. Alternatively, a co-transport 
mechanism, with one substrate stimulating the uptake of the other, is also feasible, although, 
this would need to be confirmed by measuring the transport of labeled EG, PGE2 or UA, in 
the presence of Na-Fluo. 
 
In summary, we established a novel functional assay for the investigation of the entire 
human OATP family. We demonstrate that the insect cell-based assay provides a useful 
tool for the systemic, comparative study of the function of each OATP. Functional 
characterization of the OATPs offers a chance for the discovery of inhibitors or 
activators that could lead to the identification of physiological substrates, the 
investigation of the role of SNPs in substrate recognition, and paves the way for a 
vesicle-based high-throughput screening assay.  
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Figure Captions 
 
Figure 1: Overexpression of human OATP1B1 and 1B3 results in increased Fl-MTX 
accumulation within insect cells. A: Western blot detection of human OATP1B1 and 1B3 
expressed in Sf9 insect cells. Total cell lysates (5 g) were separated on 7.5% SDS gels and 
the proteins were transferred to PVDF membranes. Anti-OATP1B1 and anti-1B3 polyclonal 
antibodies [19] (500x and 1000x dilutions, respectively) and 10,000x diluted HRP-conjugated 
anti-rabbit polyclonal antibodies were used to detect protein expression. Control (ctr.) refers 
to Sf9 cells overexpressing an unrelated protein (see Methods). The figure shows a 
representative experiment. B: Flow cytometry detection of Fl-MTX accumulation in Sf9 cells 
overexpressing an unrelated protein (control), OATP1B1 or 1B3. Cells were incubated with 
1M Fl-MTX in the presence (gray line) or absence (dashed line) of 20 M cyclosporin A 
for 10 minutes at 37
o
C, pH 7.4 (see Methods). The figure shows a representative experiment. 
C 1M Fl-MTX uptake determined by flow cytometry at different time points in the presence 
or absence of 20M cyclosporin A (CsA). The data points represent the average geomean +/- 
SD fluorescence values obtained in three independent experiments. D Accumulation (2 
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minutes) of various concentrations of Fl-MTX in insect cells was determined by flow 
cytometry. Average geomean +/- SD values of three independent experiments are shown. 
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Figure 2: Na-fluorescein uptake in Sf9 cells overexpressing human OATP1B1 or 1B3. 
A Histograms show the fluorescence of 1M Na-Fluo in Sf9 cells expressing an unrelated 
protein (control), OATP1B1 or OATP1B3 in the presence or absence of 20 M cyclosporin 
A (CsA). The result of 1 representative experiment is shown. 
B 1M Na-Fluo accumulation was measured for 0.5-20 minutes at 37oC and pH 7.4. 
Geomean fluorescence in 1B1 or 1B3-overexpressing insect cells (minus background 
fluorescence measured in unrelated virus-infected cells) was determined by flow cytometry. 
Data points represent the average of three independent experiments +/- SD values. 
C Accumulation of various concentrations (see axis x) of Na-Fluo after incubation for 4 
minutes at 37
o
C and pH 7.4 as measured by flow cytometry. Geomean values of three 
independent experiments +/- SD values are shown. 
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Figure 3: Effect of various OATP-interacting compounds on the uptake of Fl-MTX or 
Na-Fluo. Accumulation of 1M Fl-MTX or 1M Na-Fluo at 37oC for 10 minutes at pH 7.4 
was measured in the absence (nt) or presence of various compounds. Activity is determined 
by comparing the percentage of fluorescence compared to control, non-treated cells. Bars 
represent the average values of at least three independent experiments (+/- SD). nt: non-
treated control, CsA: 20 M cyclosporin A, UA: 20 M ursolic acid, CA: 150 M cholic acid, 
GC: 150 M glycocholate, TC: 150 M taurocholate, EG: 50 M estradiol 17-D-
glucuronide, PGE2: 5 M prostaglandin E2, Rif: 10 M rifampicin, and MTX: 10 M 
methotrexate. Significantly different form the non-treated control: * p< 0.05, ** p<0.01, *** 
p<0.001. 
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Figure 4: Overexpression and functional characterization of the entire human OATP 
panel in insect cells. 
A Western blot detection of various human OATPs overexpressed in insect cells. Total cell 
lysates (5 g for 1C1, 2B1, 4A1, 4C1 and 10g for 1A2, 1B1, 1B3, 2A1, 3A1, 5A1 and 6A1) 
were loaded on 7.5% Laemmli gels. After transferring onto PVDF membranes, the proteins 
were labeled with the specific antibodies (see the Methods). Control (ctr.) represents Sf9 cells 
expressing an unrelated protein. 
B and C Sf9 cells overexpressing the given OATP (see axis x) or an unrelated protein (ctr.) 
were incubated with 1M Na-Fluo (B) or 1 M Fl-MTX (C) at 37oC for 10 minutes at pH 
7.4. Intracellular fluorescence was determined by flow cytometry. Graphs show geomean 
fluorescence, bars represent the average of three independent experiments +/- SD values. 
Significantly different from the control: * p< 0.05, ** p<0.01, *** p<0.001. 
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Figure 5: Uptake of Fl-MTX and Na-Fluo using different buffers. Insect cells 
overexpressing OATP1B1 or 1B3 were incubated with 1 M Fl-MTX (panel A) or 1 M 
Na-Fluo (panel B) in various buffers with a pH range from 4.5 to 8.5 (see Methods) for 10 
minutes at 37
o
C. Values represent geomean fluorescence minus the background fluorescence 
detected in control cells. Data were obtained from three independent flow cytometry 
experiments. Bars show +/- SD values. Student’s t-test, significant difference: * p< 0.05. 
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Figure 6: Na-Fluo or Fl-MTX uptake at acidic pH in Sf9 cells overexpressing the entire 
human OATP panel. Sf9 cells overexpressing OATPs (see axis x) were incubated with 1 
M Na-Fluo (A) or 1 M Fl-MTX (B) for 10 minutes at 37oC in buffer pH 5.5 (panel A) or 
pH 6.5 (panel B). Columns show geomean fluorescence. Bars represent an average of three 
independent experiments +/- SD values. Significantly different from the control: * p< 0.05, ** 
p<0.01, *** p<0.001. 
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Figure 7: Effect of various compounds on the accumulation of Fl-MTX in insect cells 
overexpressing OATP1B1, 1A2 or 2B1. Cells were incubated with 1 M Fl-MTX at pH 6.5 
for 10 minutes in the presence or absence of various compounds. Columns represent activity 
as a percentage of non-treated (control) fluorescence measured without the added 
inhibitors/substrates. Measurements were repeated at least four times, columns show average 
+/- SD values. Striped bars indicate newly identified interactions. * p< 0.05, ** p<0.01 and 
*** p<0.001 indicate significant difference from the non-treated control. 
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Figure 8: Effect of various compounds on the accumulation of Na-Fluo in insect cells 
overexpressing the entire OATP panel (A-D). Cells were incubated with 1 M Na-Fluo at 
pH 5.5 for 10 minutes in the presence of 20 M cyclosporin A, 50 M estradiol 17-D-
glucuronide, 5 M prostaglandin E2 or 20 M ursolic acid. Columns represent activity as a 
percentage of the non-treated (control) fluorescence measured without the added 
inhibitors/substrates. Columns show average +/- SD values, n=4. Striped columns indicate 
new interactions. Significance was determined by Student’s t-test. * p< 0.05, ** p<0.01, *** 
p<0.001. 
 
